Results 61 to 70 of about 10,911,887 (292)

Suggestive Diagnostic Process in a Case of Multiple Myeloma with Gastrointestinal Immunoglobulin Light-Chain Amyloidosis Accompanied by Protein-Losing Enteropathy

Case Reports in Gastrointestinal Medicine, 2021
Multiple myeloma is a type of plasma cell neoplasm that produces monoclonal immunoglobulin. Multiple myeloma is known to cause immunoglobulin light-chain (AL) amyloidosis, which frequently involves the kidney and heart.
Katsuya Endo, Takehito Ito, Jun Nomura, Keigo Murakami, Shiho Kondo, Tomonori Satoh, Daisuke Fukushi, Yuki Yoshino, Yoshiteru Sasaki, Atsuko Takasu, Takayuki Kogure, Morihisa Hirota, Takayoshi Meguro, Kazuhiro Murakami, Junichi Kameoka, Kennichi Satoh   +15 more
doaj   +1 more source

Eprodisate for the treatment of renal disease in AA amyloidosis [PDF]

, 2007
Background: Amyloid A (AA) amyloidosis is a complication of chronic inflammatory conditions that develops when proteolytic fragments of serum amyloid A protein (SAA) are deposited in tissues as amyloid fibrils.
Dember, L.M., Hazenberg, B.P.C., Garceau, D., Puéchal, X., Livneh, A., Lesnyak, O., Skinner, Martha, Lesnyak, Olga, Livneh, Avi, Butrimiene, I., Merlini, G., Hauck, Wendy, Obici, L., Dember, Laura M., Gorevic, Peter D., Skinner, M., Butrimiene, Irena, Hawkins, Philip N., Balshaw, Robert, Hazenberg, Bouke P. C.; id_orcid, Lachmann, Helen J., Obici, Laura, Gorevic, P.D., Puechal, Xavier, Hazenberg, Bouke P. C., Hawkins, P.N., Garceau, Denis, Balshaw, R., Lachmann, H.J., Merlini, Giampaolo, Hauck, W.   +30 more
core  

Radical Resection of the Third Portion of the Duodenum for Secondary Aortoduodenal Fistula

Annals of Gastroenterological Surgery, EarlyView.
Secondary aortoduodenal fistula most commonly involves the third portion of the duodenum and requires definitive management of both vascular and gastrointestinal components. We demonstrate a step‐by‐step technique for radical duodenal resection and reconstruction performed in structured collaboration with cardiovascular surgeons.
Koji Kubota, Akira Shimizu, Tsuyoshi Notake, Tatsuichiro Seto, Yuji Soejima   +4 more
wiley   +1 more source

Exome Sequencing Uncovers Phenotypic and Genotypic Heterogeneity in 196 Indian Families Evaluated for Autoinflammatory Disorders

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Autoinflammatory disorders (AIDs) are a clinically heterogeneous group of inborn errors of immunity primarily caused by dysregulation in the innate immune system. Clinical diagnosis is often challenging due to clinical heterogeneity and the overlapping phenotypes with other inborn errors of immunity and monogenic conditions that mimic AIDs ...
Vaishnavi Ashok Badiger, Periyasamy Radhakrishnan, Suma Balan, Anand P. Rao, Prajna Udupa, Karthik Vijay Nair, Bhagesh Hunakunti, Adarsh Pooradan Prasannakumar, Sanket Limaye, Huzail Gani Shaikh, Rohit Naik, Mahesh Janarthanan, Sudharshan Sridharan, Vishal Sondhi, Sheela Nampoothiri, Hitesh Shah, Sabrinath Mahadevan, Mahabaleshwar Mamadapur, Devang Pandya, Katta Mohan Girisha, Abhay Shivpuri, Amita Moirangthem, Jyothi Raghuram, Gandham Sri Lakshmi Bhavani, Sachin Jeevanagi, Girish Subramaniam, Amita Aggarwal, Anju Shukla, Dhanya Lakshmi Narayanan   +28 more
wiley   +1 more source

Recurrent syncope and cardiac arrest in a patient with systemic light chain amyloidosis treated with bortezomib

Hematology Reports, 2016
About 10-15% of patients with multiple myeloma develop light chain (AL) amyloidosis. AL amyloidosis is a systemic disease that may involve multiple organs, often including the heart. It may present clinically with bradyarrhythmia and syncope.
Navin Jaipaul, Alexander Pi, Zhiwei Zhang   +2 more
doaj   +1 more source

Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe

British Journal of Clinical Pharmacology, EarlyView.
Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis, Christine Leopold, Joyce M. Hoek, Raymond M. Schiffelers, Marie L. De Bruin   +4 more
wiley   +1 more source

Ṭabaqāt aš-šāfiʿīya al-kubrā

, 1906
Ersch.-Jahr 1324h.In arab.
Subkī, Taqī-ad-Dīn ʿAlī Ibn-ʿAbd-al-Kāfī
core   +2 more sources

Incidence and prevalence of light chain amyloidosis in the United States in 2019–2021 using Optum EHR data

Scientific Reports
Immunoglobulin light chain amyloidosis (AL amyloidosis) is among the most common forms of systemic amyloidosis. Using electronic health records (EHR) data from the United States, we aimed to estimate the incidence and prevalence of AL amyloidosis over ...
Pedro A. Laires, Shona Fang, Jennifer Evans, Jeffrey Thompson, Abhishek Gaur, Brendon Staruk, Ankita Gupta, Richa Manwani   +7 more
doaj   +1 more source

Amyloid Light Chain Amyloidosis Involving the Heart and Temporal Arteries, Mimicking Giant Cell Arteritis

JACC: Case Reports
Background: Amyloid light chain (AL) amyloidosis is an uncommon multisystem condition. We report a globally unique case of a patient with AL amyloidosis affecting the heart and temporal arteries.
Ameer Rashed, MBBS, BSc, Ezara Fernandes, MBChB, MSc, Ritsuko Saito, BMBS, Michael Stewart, MBChB, Ernest Wong, MBBCh, BAO, BMedsci, MSc, Kaushik Guha, MBBS, BSc (Hons), MD   +5 more
doaj   +1 more source

Improving management of AL amyloidosis

Annals of the Academy of Medicine, Singapore, 2023
In this issue of the Annals, Tan et al. on behalf of Singapore Myeloma Study Group presented the consensus guidelines on light chain (AL) amyloidosis.1 This is an encouraging effort as AL amyloidosis is a rare disease, with diagnostic and therapeutic challenges.
Yuh Shan, Lee, Jeffrey, Huang
openaire   +2 more sources